On site, myotwin was represented by co-founders Dr. Jan Pietras and Andreas Meyer-Borgstädt. In numerous conversations, they showcased recent advances in human tissue models and digital heart simulations and engaged with potential partners from research, industry, and investment.
The dedicated biotech sessions at SLUSH enabled focused exchanges with key representatives from the life sciences and venture capital ecosystems. These formats offered a structured framework to discuss scientific approaches and gather feedback from various perspectives.
In addition, networking formats outside the core program, including German Beer Together and the Padel & Pitch side event, provided further opportunities for personal interaction. Padel & Pitch in particular proved to be a dynamic format that fostered professional exchange in a relaxed, sporty atmosphere and contributed to new connections in an enjoyable way.
myotwin draws a positive conclusion from its SLUSH experience and looks forward to a potential participation again next year.
About myotwin
myotwin is a biotech company specializing in human–relevant, preclinical testing systems for the development of cardiovascular drugs. With its proprietary TrinityScreen platform, myotwin enables the simultaneous measurement of contraction force, tissue stiffness, calcium dynamics, and electrical activity—directly on human heart tissue.
As a next step, myotwin is developing myoAI, a digital twin of the heart muscle that uses artificial intelligence to predict the efficacy and toxicity of drugs. This is giving rise to a new generation of precise, data-driven drug development.
The Germany-based company works closely with research institutions, industry partners, and investors to advance innovative therapies for cardiovascular diseases more quickly and in a more targeted manner. For more information, visit www.myotwin.com.
Forward–looking statements
This communication may contain forward–looking statements based on current assumptions and forecasts made by myotwin’s management. Various known and unknown risks, uncertainties, and other factors could cause the actual results, financial position, development, or performance of the company to differ materially from the estimates given here. These factors include those described in myotwin’s public reports, which are available on the myotwin website at www.myotwin.com. The company assumes no obligation to update such forward-looking statements or to adapt them to future events or developments.
